CME Group (CME) Stock Forecast & Price Target

Q: What analysts cover CME Group?

CME Group has been rated by research analysts at Barclays , Deutsche Bank Aktiengesellschaft , Erste Group Bank , Jefferies Financial Group , JPMorgan Chase & Co. , Keefe, Bruyette & Woods , Morgan Stanley , Piper Sandler , Raymond James Financial , Rothschild & Co Redburn , TD Cowen , The Goldman Sachs Group , and Weiss Ratings in the past 90 days.

$267.77 -1.76 (-0.65%)

As of 11:13 AM Eastern

Compare

CME Group - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
2

Hold
6

Buy
10

Based on 18 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 2 have given a sell rating, 6 have given a hold rating, and 10 have given a buy rating for CME.

Consensus Price Target

$305.71
14.17% Upside

According to the 18 analysts' twelve-month price targets for CME Group, the average price target is $305.71. The highest price target for CME is $353.00, while the lowest price target for CME is $209.00. The average price target represents a forecasted upside of 14.17% from the current price of $267.78.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CME Analyst Ratings Over Time

Type	Current Forecast 6/15/25 to 6/15/26	1 Month Ago 5/16/25 to 5/16/26	3 Months Ago 3/17/25 to 3/17/26	1 Year Ago 6/15/24 to 6/15/25
Strong Buy	0 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	8 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$305.71	$305.29	$304.06	$258.20
Forecasted Upside	14.17% Upside	2.15% Upside	-2.96% Downside	-4.19% Downside
Consensus Rating	Hold	Moderate Buy	Hold	Hold

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CME Group Stock vs. The Competition

Type	CME Group	Finance Companies	Broader Market
Consensus Rating Score	2.44	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	13.42% Upside	27.93% Upside	13.95% Upside
News Sentiment Rating	Positive News See Recent CME News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/11/2026	Weiss Ratings 5 of 5 stars		Downgrade	Buy (A-) ➝ Buy (B+)
6/11/2026	Rothschild & Co Redburn 4 of 5 stars	Simon Clinch Not Rated	Upgrade	Neutral ➝ Buy	$316.00 ➝ $323.00	+22.44%
6/5/2026	Erste Group Bank 2 of 5 stars		Downgrade	Buy ➝ Hold
4/23/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Benjamin Budish Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$343.00 ➝ $316.00	+10.60%
4/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$342.00 ➝ $322.00	+14.77%
4/23/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$340.00 ➝ $323.00	+13.74%
4/23/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cyprys Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$362.00 ➝ $353.00	+24.30%
4/23/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Sell	$275.00 ➝ $267.00	-5.85%
4/16/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Underweight	$266.00 ➝ $271.00	-8.75%
4/15/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Moley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$313.00 ➝ $329.00	+10.98%
Get the Latest News and Ratings for CME and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CME Group and its competitors with MarketBeat's FREE daily newsletter.
4/9/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$356.00 ➝ $349.00	+16.34%
4/8/2026	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Allen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform	$305.00	-1.80%
4/6/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$310.00 ➝ $320.00	+4.64%
3/4/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Biggar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
2/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Kramm Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$310.00	+4.24%
2/5/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashish Sabadra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$295.00 ➝ $302.00	+2.50%
12/10/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$201.00 ➝ $209.00	-21.53%
9/25/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Allen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$275.00 ➝ $300.00	+13.45%
7/24/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Owen Lau Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$300.00 ➝ $303.00	+9.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:13 AM ET.

Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, June 10, 2026. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

Here are some ways that investors could benefit from investing in CME Group Inc.:

The current stock price is around $257.40, which may present a buying opportunity for investors looking for value in the market.
CME Group Inc. has a strong market capitalization of approximately $93.27 billion, indicating a solid position in the financial markets and potential for stability.
The company has a consistent dividend payout, with an annualized dividend of $5.20, providing a yield of 2.0%, which can be attractive for income-focused investors.
Recent analyst reports show a mix of ratings, with several firms maintaining a "buy" rating, suggesting confidence in the company's future performance.
CME Group Inc. operates some of the largest derivatives exchanges globally, offering a diverse range of products, which can help mitigate risks and attract a broad client base.

CME Group
Bear Case

Investors should be bearish about investing in CME Group Inc. for these reasons:

Recent insider selling, with a notable decrease in positions by executives, may raise concerns about the company's future prospects and insider confidence.
Some analysts have downgraded their ratings, with Wall Street Zen moving from a "hold" to a "sell" rating, indicating potential caution among market experts.
The stock has experienced fluctuations, with a 52-week high of $329.16 and a low of $244.56, suggesting volatility that could deter risk-averse investors.
The company's debt-to-equity ratio is relatively low at 0.13, which is generally positive, but it may indicate limited leverage for growth opportunities compared to competitors.
Market conditions can impact trading volumes and revenues, and any downturn in the financial markets could adversely affect CME Group Inc.'s performance.

CME Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $305.71, with a high forecast of $353.00 and a low forecast of $209.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.

According to analysts, CME Group's stock has a predicted upside of 14.17% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 2 downgrades and 1 upgrade by analysts.

CME Group has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Erste Group Bank, Jefferies Financial Group, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Piper Sandler, Raymond James Financial, Rothschild & Co Redburn, TD Cowen, The Goldman Sachs Group, and Weiss Ratings in the past 90 days.

Analysts like CME Group more than other "finance" companies. The consensus rating score for CME Group is 2.44 while the average consensus rating score for "finance" companies is 2.30. Learn more on how CME compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With CME Group Recommendations

This page (NASDAQ:CME) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CME Group (CME) Stock Forecast & Price Target